Johns Hopkins University, on behalf of its School of Medicine (JHU) and Alkem Laboratories, have entered into an exclusive license agreement for the development and commercialization of JHU's novel target and technology that will help patients with colorectal cancer. This technology, a novel target, will serve as a bona fide biomarker and antagonist in human colorectal cancer based on angiogenesis and inflammation.

According to Alkem's Managing Director, Sandeep Singh: "This collaboration is a stepping stone to a long-term symbiotic relationship between JHU and Alkem, to help bring novel therapies to market".

Alkem's President & Chief Medical Officer, Dr. Akhilesh Shama stated: "We aspire that this will be a significant step in fostering continued academic and clinical collaboration between Alkem and JHU for addressing unmet patient needs." He further added that, “Alkem will be working with the Director of the Sphingolipid Signaling and Vascular Biology Laboratory at the Johns Hopkins University School of Medicine on this novel target". Alkem acknowledges Jay Nadkarni's role in the said collaboration.